Northwest Biotherapeutics Inc. Files SEC Form SC 13G, Statement of Acquisition of Beneficial Ownership By Individuals (Apr. 7, 2015)

By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing by Northwest Biotherapeutics Inc. (Form SC 13G) was posted on April 7, 2015.

The SIC code for this company is 2834, Pharmaceutical Preparations.

There was one document filed with this form. The SEC file number is 0001213900-15-002500.

The contact information for this company is 4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814, (240) 497-9024.

Our editors provided additional information about Form SC 13G: Schedule 13G is a much abbreviated version of Schedule 13D that is only available for use by a limited category of "persons" (such as banks, broker/dealers, and insurance companies) and even then only when the securities were acquired in the ordinary course of business and not with the purpose or effect of changing or influencing the control of the issuer.

A U.S. Securities and Exchange Commission filing is a formal document or financial statement submitted to the SEC by publicly-traded companies.

For additional information on this SEC filing see: http://www.sec.gov/Archives/edgar/data/1072379/0001213900-15-002500-index.html.

Keywords for this news article include: Pharmaceutical Company, Pharmaceutical Preparations, SEC Filing, Biotechnology Companies, Northwest Biotherapeutics Inc..

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2015, NewsRx LLC